The median PFS of patients treated with palbociclib and fulvestrant was significantly better in the KRAS wild-type ctDNA group (= 49; median, 17.8; range: 17.2not achieved) than in the mutKRAS group (= 57; median PFS, 3 months, range 1C6.1 months, 95%CI 0.8C3.6) (HR, 20.746;95%CI,9.576C44.946; 0.001). challenge which is definitely poorly Continue Reading